<DOC>
	<DOCNO>NCT01329406</DOCNO>
	<brief_summary>The present study aim evaluate efficacy milnacipran treatment pain due osteoarthritis ( OA ) , , determine whether milnacipran provide superior efficacy placebo patient OA . Milnacipran serotonin-norepinephrine reuptake inhibitor ( SNRI ) currently approve United States treatment major depressive disorder fibromyalgia . There increased evidence suggest SNRIs may effective treatment chronic pain condition , OA . The hypothesis study survival time ( time randomization loss efficacy ) milnacipran group superior placebo group .</brief_summary>
	<brief_title>Study Evaluate Efficacy Milnacipran Treatment Pain Due Osteoarthritis</brief_title>
	<detailed_description>The study design Double-Blind , Placebo-Controlled , Enriched Enrollment Randomized Withdrawal Study . This mean , upon entry study , subject enter open-label period take milnacipran 4 week . Subjects taper dose one 100mg tablet twice daily total 200mg per day . After 4 week , subject return clinic re-evaluated . Only subject meet certain criterion randomize continue double-blind period study . Once subject randomize , take either milnacipran placebo another 4 week . Following double-blind period , subject taper study medication receive phone call week 2 week follow-up assessment . Throughout study , subject complete various questionnaire test procedure aim sub-typing subject base pain mechanism .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Be 2175 year age good general medical psychological health Be able speak , read , write , understand English , understand consent form , complete study related procedure , communicate study staff Have negative urine pregnancy test screening , use appropriate birth control Have document painful Osteoarthritis ( OA ) least one knee least 6 month ; OA Class IIII meet American College Rheumatology ( ACR ) clinical classification criterion , define : 1 . Knee pain least 3 follow 6 : Age &gt; 50 Morning stiffness &lt; 30 minute Crepitus active motion Bony tenderness Bony enlargement No palpable warmth synovium 2 . The target joint must contain type orthopedic and/or prosthetic device Have target joint pain average 5 day per week average pain intensity least 4/10 010 NRS last 24 hour prior screen Have stable treatment modality , e.g . acupuncture , physical therapy Be willing stop take Nonsteroidal Antiinflammatory drug ( NSAIDs ) opioids duration study Are allergic intolerant SNRI ; previous poor response SNRI OA pain ; currently take SNRI tricyclic antidepressant Have body mass index ( BMI ) &gt; 40 kg/m2 Have Hospital Anxiety Depression Scale ( HADS ) score &gt; 12 either subscale establish history major depressive disorder control medication Have significant pain outside target knee , include significant hip back pain . ( Bilateral knee OA allow . ) Have pain affecting target knee due etiology OA Have document history inflammatory arthritis include rheumatoid arthritis Have local injection target joint within past 3 month prior screen Have oral intramuscular corticosteroid within past 30 day Have worker 's compensation claim , disability , litigation Have know history uncontrolled narrowangle glaucoma Have know history suicidal ideation Use monoamine oxidase inhibitor ( MAOI ) concomitantly Are allergic intolerant acetaminophen Using opioids 4 day per week month precede screen visit Have significant history renal impairment/failure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Osteoarthritis ( OA )</keyword>
	<keyword>Milnacipran</keyword>
	<keyword>Serotonin-norepinephrine reuptake inhibitor ( SNRI )</keyword>
	<keyword>Knee pain</keyword>
</DOC>